vs
Cytosorbents Corp（CTSO）与RIVERVIEW BANCORP INC（RVSB）财务数据对比。点击上方公司名可切换其他公司
RIVERVIEW BANCORP INC的季度营收约是Cytosorbents Corp的1.5倍（$14.0M vs $9.2M），RIVERVIEW BANCORP INC净利率更高（9.8% vs -59.5%，领先69.3%），RIVERVIEW BANCORP INC同比增速更快（10.4% vs 0.9%），RIVERVIEW BANCORP INC自由现金流更多（$-736.0K vs $-4.9M），过去两年RIVERVIEW BANCORP INC的营收复合增速更高（24.6% vs 1.3%）
Cytosorbents是一家公开上市企业，总部位于美国新泽西州普林斯顿，专注于血液净化领域相关医疗产品的研发与商业化，核心产品应用于重症救治场景，帮助去除患者血液中的炎性介质等有害物质。
Riverview Bancorp Inc.是一家总部位于美国的银行控股公司，主营个人与商业银行业务，服务覆盖太平洋西北地区，提供存款、消费贷款、住房抵押贷款、商业信贷及小企业金融等产品，服务零售客户与本地企业群体。
CTSO vs RVSB — 直观对比
营收规模更大
RVSB
是对方的1.5倍
$9.2M
营收增速更快
RVSB
高出9.5%
0.9%
净利率更高
RVSB
高出69.3%
-59.5%
自由现金流更多
RVSB
多$4.2M
$-4.9M
两年增速更快
RVSB
近两年复合增速
1.3%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $9.2M | $14.0M |
| 净利润 | $-5.5M | $1.4M |
| 毛利率 | 73.7% | — |
| 营业利润率 | -47.5% | 12.4% |
| 净利率 | -59.5% | 9.8% |
| 营收同比 | 0.9% | 10.4% |
| 净利润同比 | 27.4% | 11.8% |
| 每股收益（稀释后） | $-0.09 | $0.07 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CTSORVSB
| Q4 25 | $9.2M | $14.0M | ||
| Q3 25 | $9.5M | $13.6M | ||
| Q2 25 | $9.6M | $13.3M | ||
| Q1 25 | $8.7M | $12.9M | ||
| Q4 24 | $9.2M | $12.7M | ||
| Q3 24 | $8.6M | $12.8M | ||
| Q2 24 | $8.8M | $12.2M | ||
| Q1 24 | $9.0M | $9.0M |
净利润CTSORVSB
| Q4 25 | $-5.5M | $1.4M | ||
| Q3 25 | $-3.2M | $1.1M | ||
| Q2 25 | $1.9M | $1.2M | ||
| Q1 25 | $-1.5M | $1.1M | ||
| Q4 24 | $-7.6M | $1.2M | ||
| Q3 24 | $-2.8M | $1.6M | ||
| Q2 24 | $-4.3M | $966.0K | ||
| Q1 24 | $-6.1M | $-3.0M |
毛利率CTSORVSB
| Q4 25 | 73.7% | — | ||
| Q3 25 | 70.3% | — | ||
| Q2 25 | 70.9% | — | ||
| Q1 25 | 71.1% | — | ||
| Q4 24 | 68.4% | — | ||
| Q3 24 | 61.0% | — | ||
| Q2 24 | 73.5% | — | ||
| Q1 24 | 76.5% | — |
营业利润率CTSORVSB
| Q4 25 | -47.5% | 12.4% | ||
| Q3 25 | -30.2% | 10.2% | ||
| Q2 25 | -37.6% | 11.7% | ||
| Q1 25 | -44.5% | 11.3% | ||
| Q4 24 | -37.1% | 12.4% | ||
| Q3 24 | -56.1% | 15.5% | ||
| Q2 24 | -40.4% | 10.0% | ||
| Q1 24 | -51.8% | -47.5% |
净利率CTSORVSB
| Q4 25 | -59.5% | 9.8% | ||
| Q3 25 | -33.4% | 8.1% | ||
| Q2 25 | 20.2% | 9.2% | ||
| Q1 25 | -16.9% | 8.9% | ||
| Q4 24 | -82.7% | 9.7% | ||
| Q3 24 | -32.1% | 12.2% | ||
| Q2 24 | -48.6% | 7.9% | ||
| Q1 24 | -67.7% | -34.7% |
每股收益（稀释后）CTSORVSB
| Q4 25 | $-0.09 | $0.07 | ||
| Q3 25 | $-0.05 | $0.05 | ||
| Q2 25 | $0.03 | $0.06 | ||
| Q1 25 | $-0.02 | $0.05 | ||
| Q4 24 | $-0.14 | $0.06 | ||
| Q3 24 | $-0.05 | $0.07 | ||
| Q2 24 | $-0.08 | $0.05 | ||
| Q1 24 | $-0.11 | $-0.14 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $6.2M | $28.6M |
| 总债务越低越好 | — | — |
| 股东权益账面价值 | $5.9M | $164.2M |
| 总资产 | $44.2M | $1.5B |
| 负债/权益比越低杠杆越低 | — | — |
8季度趋势，按日历期对齐
现金及短期投资CTSORVSB
| Q4 25 | $6.2M | $28.6M | ||
| Q3 25 | $7.5M | $32.8M | ||
| Q2 25 | $10.2M | $34.2M | ||
| Q1 25 | $11.6M | $29.4M | ||
| Q4 24 | $3.3M | $25.3M | ||
| Q3 24 | $5.7M | $31.0M | ||
| Q2 24 | $8.5M | $27.8M | ||
| Q1 24 | $8.6M | $23.6M |
总债务CTSORVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | $13.8M | — | ||
| Q2 24 | $13.7M | — | ||
| Q1 24 | $4.4M | — |
股东权益CTSORVSB
| Q4 25 | $5.9M | $164.2M | ||
| Q3 25 | $9.0M | $163.5M | ||
| Q2 25 | $11.6M | $162.0M | ||
| Q1 25 | $14.5M | $160.0M | ||
| Q4 24 | $11.1M | $158.3M | ||
| Q3 24 | $13.4M | $160.8M | ||
| Q2 24 | $17.4M | $155.9M | ||
| Q1 24 | $19.6M | $155.6M |
总资产CTSORVSB
| Q4 25 | $44.2M | $1.5B | ||
| Q3 25 | $45.8M | $1.5B | ||
| Q2 25 | $48.0M | $1.5B | ||
| Q1 25 | $50.8M | $1.5B | ||
| Q4 24 | $47.4M | $1.5B | ||
| Q3 24 | $47.8M | $1.5B | ||
| Q2 24 | $53.4M | $1.5B | ||
| Q1 24 | $47.1M | $1.5B |
负债/权益比CTSORVSB
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 1.03× | — | ||
| Q2 24 | 0.78× | — | ||
| Q1 24 | 0.23× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-4.8M | $-506.0K |
| 自由现金流经营现金流 - 资本支出 | $-4.9M | $-736.0K |
| 自由现金流率自由现金流/营收 | -53.4% | -5.2% |
| 资本支出强度资本支出/营收 | 1.2% | 1.6% |
| 现金转化率经营现金流/净利润 | — | -0.37× |
| 过去12个月自由现金流最近4个季度 | $-12.5M | $20.4M |
8季度趋势，按日历期对齐
经营现金流CTSORVSB
| Q4 25 | $-4.8M | $-506.0K | ||
| Q3 25 | $-2.6M | $16.8M | ||
| Q2 25 | $-1.5M | $-697.0K | ||
| Q1 25 | $-3.5M | $8.3M | ||
| Q4 24 | $-2.3M | $2.2M | ||
| Q3 24 | $-2.5M | $764.0K | ||
| Q2 24 | $-4.8M | $5.4M | ||
| Q1 24 | $-4.8M | $12.8M |
自由现金流CTSORVSB
| Q4 25 | $-4.9M | $-736.0K | ||
| Q3 25 | $-2.6M | $16.4M | ||
| Q2 25 | $-1.5M | $-773.0K | ||
| Q1 25 | $-3.5M | $5.6M | ||
| Q4 24 | $-2.4M | $1.9M | ||
| Q3 24 | $-2.6M | $-1.4M | ||
| Q2 24 | $-4.8M | $5.3M | ||
| Q1 24 | $-4.9M | $7.1M |
自由现金流率CTSORVSB
| Q4 25 | -53.4% | -5.2% | ||
| Q3 25 | -27.3% | 120.1% | ||
| Q2 25 | -16.1% | -5.8% | ||
| Q1 25 | -39.7% | 43.1% | ||
| Q4 24 | -26.3% | 15.0% | ||
| Q3 24 | -30.4% | -11.3% | ||
| Q2 24 | -54.4% | 43.7% | ||
| Q1 24 | -54.2% | 79.0% |
资本支出强度CTSORVSB
| Q4 25 | 1.2% | 1.6% | ||
| Q3 25 | 0.2% | 2.9% | ||
| Q2 25 | 0.4% | 0.6% | ||
| Q1 25 | 0.0% | 21.0% | ||
| Q4 24 | 0.8% | 2.4% | ||
| Q3 24 | 1.8% | 17.3% | ||
| Q2 24 | 0.2% | 0.9% | ||
| Q1 24 | 0.5% | 62.0% |
现金转化率CTSORVSB
| Q4 25 | — | -0.37× | ||
| Q3 25 | — | 15.25× | ||
| Q2 25 | -0.78× | -0.57× | ||
| Q1 25 | — | 7.20× | ||
| Q4 24 | — | 1.79× | ||
| Q3 24 | — | 0.49× | ||
| Q2 24 | — | 5.63× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CTSO
| Direct | $5.1M | 55% |
| Distributors And Strategic Partners | $4.2M | 45% |
RVSB
暂无分部数据
